LAG-3
5 abstracts
Abstract
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).Org: Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel,
Abstract
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Chinese Academy of Sciences,
Abstract
Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma.Org: University of Pretoria, Steve Biko Academic Hospital, The Medical Oncology Centre of Rosebank,
Abstract
Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple negative breast cancer (TNBC) and non-TNBC.Org: The Medical Oncology Centre of Rosebank, Johannesburg, South Africa, Department of Immunology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa, University of Pretoria, Department of Immunology, Pretoria, South Africa, Netcare, City of Johannesburg, South Africa, Drs Gritzman and Thatcher Inc. Pathology Laboratory, City of Johannesburg, South Africa,
Abstract
Uncovering LAG-3 related tumor immunology in renal cell carcinoma and pan-cancer evaluation.Org: Department of Urology, Nerima General Hospital, Tokyo, Japan, Department of Urology, Keio University School of Medicine, Tokyo, Japan, Department of Urology, Keio University School of Medicine, Shinjuku-Ku, Japan,